Basic Information
| LncRNA/CircRNA Name | HAS2-AS1 |
| Synonyms | NA |
| Region | GRCh38_8:121639293-121644693 |
| Ensemble | ENSG00000248690 |
| Refseq | NR_002835 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioblastoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
| Sample | Glioma cell lines (LN229, U87, U118, T98, and A172), The primary GBM cells (PG1 and PG2), glioma tissues, normal brain tissue, glioma tissues, normal brain tissue |
| Expression Pattern | up-regulated |
| Function Description | It was discovered that HAS2-AS1 was elevated in glioma tissues and correlated with the prognosis of patients with glioma. Reduction of HAS2-AS1 suppressed the migration and invasion in vitro and in vivo. The transcription factor STAT1 could raise HAS2-AS1 by binding to its promoter region. Besides, HAS2-AS1 could adjust PRPS1 via sponging miR-608 in a direct manner. |
| Pubmed ID | 31385362 |
| Year | 2019 |
| Title | Long noncoding RNA HAS2-AS1 promotes tumor progression in glioblastoma via functioning as a competing endogenous RNA |
External Links
| Links for HAS2-AS1 | GenBank HGNC NONCODE |
| Links for glioblastoma | OMIM COSMIC |